These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21628837)

  • 21. Predictors and Long-Term Clinical Impact of Acute Stent Malapposition: An Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Intravascular Ultrasound Substudy.
    Wang B; Mintz GS; Witzenbichler B; Souza CF; Metzger DC; Rinaldi MJ; Duffy PL; Weisz G; Stuckey TD; Brodie BR; Matsumura M; Yamamoto MH; Parvataneni R; Kirtane AJ; Stone GW; Maehara A
    J Am Heart Assoc; 2016 Dec; 5(12):. PubMed ID: 28007741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.
    Habara S; Kadota K; Shimada T; Ohya M; Amano H; Izawa Y; Kubo S; Hyodo Y; Otsuru S; Hasegawa D; Tada T; Tanaka H; Fuku Y; Goto T; Mitsudo K
    J Am Coll Cardiol; 2015 Jul; 66(1):14-22. PubMed ID: 26139053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.
    Abizaid A; Costa JR; Banning A; Bartorelli AL; Dzavik V; Ellis S; Gao R; Holmes DR; Jeong MH; Legrand V; Neumann FJ; Nyakern M; Orlick A; Spaulding C; Worthley S; Urban PM;
    JACC Cardiovasc Interv; 2012 Jan; 5(1):64-71. PubMed ID: 22230152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis.
    Cook S; Ladich E; Nakazawa G; Eshtehardi P; Neidhart M; Vogel R; Togni M; Wenaweser P; Billinger M; Seiler C; Gay S; Meier B; Pichler WJ; Jüni P; Virmani R; Windecker S
    Circulation; 2009 Aug; 120(5):391-9. PubMed ID: 19620501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of drug-eluting stent and conventional therapies in coronary heart disease patients with in-stent restenosis: a meta-analysis.
    Sun Y; Li L; Su Q; Lu Y
    Cell Biochem Biophys; 2014 Jan; 68(1):211-29. PubMed ID: 23784750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stent thrombosis and drug-eluting stents.
    Takayama T; Hiro T; Hirayama A
    J Cardiol; 2011 Sep; 58(2):92-8. PubMed ID: 21839615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART).
    Kimura T; Morimoto T; Kozuma K; Honda Y; Kume T; Aizawa T; Mitsudo K; Miyazaki S; Yamaguchi T; Hiyoshi E; Nishimura E; Isshiki T;
    Circulation; 2010 Jul; 122(1):52-61. PubMed ID: 20566955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study.
    Witzenbichler B; Maehara A; Weisz G; Neumann FJ; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Stuckey TD; Mazzaferri EL; Xu K; Parise H; Mehran R; Mintz GS; Stone GW
    Circulation; 2014 Jan; 129(4):463-70. PubMed ID: 24281330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year clinical follow up of coronary drug-eluting stent in patients at high risk for coronary restenosis.
    Azzarelli S; Amico F; Galassi AR; Giacoppo M; Argentino V; Fiscella A
    J Invasive Cardiol; 2008 Feb; 20(2):62-6. PubMed ID: 18252969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do patients with drug-eluting stent thrombosis have a similar prognosis to patients presenting with st-Elevation myocardial infarction of de novo lesions?
    Belle L; Mahmoudi M; Delhaye C; Ben-Dor I; Maluenda G; Gaglia MA; Torguson R; Satler LF; Pichard AD; Waksman R
    J Interv Cardiol; 2011 Aug; 24(4):320-5. PubMed ID: 21535151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
    Qasim A; Cosgrave J; Latib A; Colombo A
    Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study.
    Gyöngyösi M; Christ G; Lang I; Kreiner G; Sochor H; Probst P; Neunteufl T; Badr-Eslam R; Winkler S; Nyolczas N; Posa A; Leisch F; Karnik R; Siostrzonek P; Harb S; Heigert M; Zenker G; Benzer W; Bonner G; Kaider A; Glogar D;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):718-27. PubMed ID: 19695539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: rationale and safety.
    Prasad SB; David T; Malaiapan Y; Cameron JD; Meredith IT
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):193-200. PubMed ID: 20549694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.